Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 2/20 | 0.51 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486079 | 0.82 | SMN1; SMN2 (0.50) | ITGAVFABP4SMN1; SMN2MAPTKAT6A | |
| SCHEMBL15467870 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1USP2POLBL3MBTL1 | |
| SCHEMBL3203408 | 0.81 | FABP4 (0.60) | ITGAVFABP4SMN1; SMN2MAPTKAT6A | |
| SCHEMBL3564486 | 0.80 | L3MBTL1 (0.64) | SMN1; SMN2ALDH1A1USP2HSD17B10POLB | |
| SCHEMBL2676737 | 0.79 | FABP4 (0.67) | FABP4ALDH1A1L3MBTL1CA12CA9 | |
| SCHEMBL7552123 | 0.79 | KAT6A (0.52) | ITGAVKAT6APKMNAMPTHTR6 | |
| SCHEMBL4183041 | 0.78 | MAPT (0.68) | ITGAVFABP4SMN1; SMN2MAPTKAT6A | |
| SCHEMBL4617734 | 0.78 | ALDH1A1 (0.63) | FABP4SMN1; SMN2ALDH1A1USP2HSD17B10 | |
| Hydrochloric Acid SCHEMBL27202572 | 0.78 | CYP3A4 (0.51) | SMN1; SMN2KAT6AALDH1A1USP2HSD17B10 | |
| SCHEMBL29695202 | 0.77 | FABP4 (0.61) | FABP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ITGAV 4233/4885FABP4 4456/4885SMN1; SMN2 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.